Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + pemetrexed
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bevacizumab + pemetrexed is a combination therapy used primarily in the treatment of advanced nonsquamous non-small-cell lung cancer (NSCLC) and has also shown efficacy in recurrent and metastatic cervical cancer. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A), thereby blocking the formation of new blood vessels necessary for tumor growth. Pemetrexed is a small molecule antimetabolite that disrupts folate-dependent metabolic processes essential for cell replication, inhibiting enzymes involved in purine and pyrimidine synthesis. The combination leverages both antiangiogenic and cytotoxic mechanisms to improve clinical outcomes, including progression-free survival, compared to monotherapy with either agent[1][2][3][5].
- Brand names
- AvastinAlimta
- Other names
- low-dose-bevacizumab/pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)GART (GAR transformylase)
Beyond the preview
Go deeper on bevacizumab + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + pemetrexed.